Literature DB >> 15622444

Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjögren's syndrome with a special emphasis on BAFF.

Peter Szodoray1, Stig Jellestad, Philip Alex, Tong Zhou, Patrick C Wilson, Michael Centola, Johan G Brun, Roland Jonsson.   

Abstract

Functionally impaired B cells play an important role in the pathogenesis of Sjögren's syndrome (SS). The aim of the study was to investigate the apoptosis susceptibility of peripheral blood B cells from patients with SS and the impact of B cell activating factor (BAFF) on the apoptosis capability of these cells in correlation with IgG production. Peripheral blood B cells were isolated and stained for apoptosis markers (Bax, Bcl-2) and members of the TNF-R superfamily, CD95 and CD40. The apoptosis frequency of cells bearing these markers were assessed. Also, the apoptosis capability of cultured B-lymphocytes was investigated in medium alone, with anti-CD95 or with soluble BAFF. Quantitative ELISA was performed to detect plasma levels of sBAFF. Furthermore, the level of circulating B-cell cytokines was measured. BAFF levels were compared between patients with normal and elevated IgG levels. In SS, Bcl-2 positive B cell counts were significantly higher then in controls, also in this population the apoptosis frequency was reduced. Apoptosis within Bax+ and CD40+ B cells were significantly decreased in patients. BAFF induced a significant antiapoptotic effect in SS; also this effect was clearly evident in B cells from SS with hypergammaglobulinaemia. Plasma BAFF levels were significantly higher in SS, mostly in patients with hypergammaglobulinaemia. Plasma B-cell cytokines were raised in SS. In Sjögren's syndrome B cells, a general antiapoptotic tendency might lead to prolonged B-cell survival driven at least partly by elevated levels of BAFF and supposedly by B-cell cytokines. Also, the exaggerated BAFF stimulation might lead to excessive immunoglobulin production. The B-cell apoptosis defects, the increased BAFF levels-correlating with hypergammaglobulinaemia-together with the raised B-cell cytokine levels indicates the disturbed B-cell biology in the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15622444     DOI: 10.1007/s10875-004-6240-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  33 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  CD40, CD154, Bax and Bcl-2 expression in Sjögren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases.

Authors:  M Ohlsson; P Szodoray; L L Loro; A C Johannessen; R Jonsson
Journal:  Scand J Immunol       Date:  2002-12       Impact factor: 3.487

3.  Cutting edge: A/WySnJ transitional B cells overexpress the chromosome 15 proapoptotic Blk gene and succumb to premature apoptosis.

Authors:  I J Amanna; K Clise-Dwyer; F E Nashold; K A Hoag; C E Hayes
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

4.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

5.  Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

Authors:  Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

6.  BAFFled B cells survive and thrive: roles of BAFF in B-cell development.

Authors:  Antonius G Rolink; Fritz Melchers
Journal:  Curr Opin Immunol       Date:  2002-04       Impact factor: 7.486

7.  Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjögren's syndrome.

Authors:  S Salomonsson; P Larsson; P Tengnér; E Mellquist; P Hjelmström; M Wahren-Herlenius
Journal:  Scand J Immunol       Date:  2002-04       Impact factor: 3.487

8.  Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.

Authors:  Bing He; Amy Chadburn; Erin Jou; Elaine J Schattner; Daniel M Knowles; Andrea Cerutti
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

9.  SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder.

Authors:  William Stohl
Journal:  Arthritis Res Ther       Date:  2003-03-27       Impact factor: 5.156

10.  B cells, BAFF/zTNF4, TACI, and systemic lupus erythematosus.

Authors:  T Dörner; C Putterman
Journal:  Arthritis Res       Date:  2001-03-20
View more
  12 in total

1.  Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  Jérémie Sellam; Corinne Miceli-Richard; Jacques-Eric Gottenberg; Marc Ittah; Frédéric Lavie; Christine Lacabaratz; Nicolas Gestermann; Alexis Proust; Olivier Lambotte; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-12-21       Impact factor: 19.103

Review 2.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 3.  Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease.

Authors:  Cuong Q Nguyen; Ammon B Peck
Journal:  Ocul Surf       Date:  2009-01       Impact factor: 5.033

4.  Treating Sjögren's Syndrome: Insights for the Clinician.

Authors:  Claudio Vitali; Gianluigi Palombi; Pierluigi Cataleta
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

5.  Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome.

Authors:  Malin V Jonsson; Peter Szodoray; Stig Jellestad; Roland Jonsson; Kathrine Skarstein
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

Review 6.  Cytokines in Sjögren's syndrome.

Authors:  N Roescher; P P Tak; G G Illei
Journal:  Oral Dis       Date:  2009-06-10       Impact factor: 3.511

Review 7.  Sjögren's syndrome in older patients: aetiology, diagnosis and management.

Authors:  Rada V Moerman; Hendrika Bootsma; Frans G M Kroese; Arjan Vissink
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

8.  No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome.

Authors:  Jacques-Eric Gottenberg; Jérémie Sellam; Marc Ittah; Frédéric Lavie; Alexis Proust; Habib Zouali; Christelle Sordet; Jean Sibilia; Robert P Kimberly; Xavier Mariette; Corinne Miceli-Richard
Journal:  Arthritis Res Ther       Date:  2006-01-09       Impact factor: 5.156

9.  B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.

Authors:  Marc Ittah; Corinne Miceli-Richard; Jacques- Eric Gottenberg; Frédéric Lavie; Thierry Lazure; Nathalie Ba; Jérémie Sellam; Christine Lepajolec; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2006-02-28       Impact factor: 5.156

Review 10.  B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.

Authors:  Arne Hansen; Peter E Lipsky; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.